[
  {
    "ts": "2025-10-23T20:12:33+00:00",
    "headline": "Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies",
    "summary": "Viking Therapeutics stock popped Thursday on the lightning pace it's enrolling patients in a pair of obesity treatment tests.",
    "url": "https://www.investors.com/news/technology/viking-therapeutics-stock-obesity-treatment-studies/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "0001597a-8634-392d-a8e4-1e53ec92cdcc",
      "content": {
        "id": "0001597a-8634-392d-a8e4-1e53ec92cdcc",
        "contentType": "STORY",
        "title": "Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies",
        "description": "",
        "summary": "Viking Therapeutics stock popped Thursday on the lightning pace it's enrolling patients in a pair of obesity treatment tests.",
        "pubDate": "2025-10-23T20:12:33Z",
        "displayTime": "2025-10-23T20:12:33Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/0001597a-8634-392d-a8e4-1e53ec92cdcc/viking-bolts-higher-on.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/2787fbf97c7f5ace6174d7dff3413cd4",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9jT86StQKHRPdn8CqhzWAw--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/2787fbf97c7f5ace6174d7dff3413cd4.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kqz88mLH3fG9HFQ8lW43rw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/2787fbf97c7f5ace6174d7dff3413cd4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/viking-therapeutics-stock-obesity-treatment-studies/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T15:30:00+00:00",
    "headline": "Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033 | Astute Analytica",
    "summary": "Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025–2033. The radiop",
    "url": "https://finance.yahoo.com/news/radiopharmaceuticals-market-reach-us-13-153000786.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "2bf17e07-9abb-3489-b9c6-0f0d41f298d8",
      "content": {
        "id": "2bf17e07-9abb-3489-b9c6-0f0d41f298d8",
        "contentType": "STORY",
        "title": "Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033 | Astute Analytica",
        "description": "",
        "summary": "Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025–2033. The radiop",
        "pubDate": "2025-10-23T15:30:00Z",
        "displayTime": "2025-10-23T15:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JHwPm5XOBkH6S4g8iMmLiw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SbelUm4u7tLxgdG5STxR1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/radiopharmaceuticals-market-reach-us-13-153000786.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/radiopharmaceuticals-market-reach-us-13-153000786.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T14:39:00+00:00",
    "headline": "Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?",
    "summary": "Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.",
    "url": "https://finance.yahoo.com/news/lilly-10-month-buy-sell-143900884.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1ec8677d-8d39-301b-a5d6-d50edf5cd483",
      "content": {
        "id": "1ec8677d-8d39-301b-a5d6-d50edf5cd483",
        "contentType": "STORY",
        "title": "Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?",
        "description": "",
        "summary": "Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.",
        "pubDate": "2025-10-23T14:39:00Z",
        "displayTime": "2025-10-23T14:39:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-10-month-buy-sell-143900884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-10-month-buy-sell-143900884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T14:00:31+00:00",
    "headline": "Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?",
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-earnings-expected-140031100.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "12b79267-2e64-3d54-ab6c-ba007132194b",
      "content": {
        "id": "12b79267-2e64-3d54-ab6c-ba007132194b",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?",
        "description": "",
        "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2025-10-23T14:00:31Z",
        "displayTime": "2025-10-23T14:00:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a",
          "originalWidth": 900,
          "originalHeight": 476,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5btkEdScc6bMd.LwAmujVg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a.cf.webp",
              "width": 900,
              "height": 476,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PSL6wqVlNgtKuHixyahWwA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-earnings-expected-140031100.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-earnings-expected-140031100.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T13:55:00+00:00",
    "headline": "How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?",
    "summary": "Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.",
    "url": "https://finance.yahoo.com/news/ozempic-wegovy-sales-aid-nvos-135500915.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3d2985e0-141c-3754-a893-a2998bad2828",
      "content": {
        "id": "3d2985e0-141c-3754-a893-a2998bad2828",
        "contentType": "STORY",
        "title": "How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?",
        "description": "",
        "summary": "Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.",
        "pubDate": "2025-10-23T13:55:00Z",
        "displayTime": "2025-10-23T13:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JLDGQt80ARh3qkafoo9TaA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ncdWYZW_rP_HUKWXjdodfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ozempic-wegovy-sales-aid-nvos-135500915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ozempic-wegovy-sales-aid-nvos-135500915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T11:40:20+00:00",
    "headline": "Is Novo Nordisk (NVO) The Best Weight-Loss Stock to Buy?",
    "summary": "We recently published 10 Trending Stocks Moving These Days. Novo Nordisk A/S (NYSE:NVO) is one of the trending stocks moving these days. Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the company’s weight-loss drug business. “All this talk about GLP-1s? No, I’m not […]",
    "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-best-weight-114020864.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "384f38c3-81be-39e6-a1de-ffac5704cf99",
      "content": {
        "id": "384f38c3-81be-39e6-a1de-ffac5704cf99",
        "contentType": "STORY",
        "title": "Is Novo Nordisk (NVO) The Best Weight-Loss Stock to Buy?",
        "description": "",
        "summary": "We recently published 10 Trending Stocks Moving These Days. Novo Nordisk A/S (NYSE:NVO) is one of the trending stocks moving these days. Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the company’s weight-loss drug business. “All this talk about GLP-1s? No, I’m not […]",
        "pubDate": "2025-10-23T11:40:20Z",
        "displayTime": "2025-10-23T11:40:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1092263815dd21c69f3a1b84d83fb918",
          "originalWidth": 750,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3I89SP284cVmnVhQ7hRqIg--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1092263815dd21c69f3a1b84d83fb918.cf.webp",
              "width": 750,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KDNLKpvGBX.9S9UtBHEW5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1092263815dd21c69f3a1b84d83fb918.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-best-weight-114020864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-best-weight-114020864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T10:30:00+00:00",
    "headline": "Good Omen, or Bad? Tesla Opens Mag 7 Earnings Season to Mixed Reviews",
    "summary": "The all-powerful cohort continues to define the broader market, which has officially been placed on the “bubble watchlist.”",
    "url": "https://www.thedailyupside.com/technology/artificial-intelligence/tesla-kicks-off-mag-7-earnings-season/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "9371a1e8-68a5-3a8d-b9a6-b2896de93463",
      "content": {
        "id": "9371a1e8-68a5-3a8d-b9a6-b2896de93463",
        "contentType": "STORY",
        "title": "Good Omen, or Bad? Tesla Opens Mag 7 Earnings Season to Mixed Reviews",
        "description": "",
        "summary": "The all-powerful cohort continues to define the broader market, which has officially been placed on the “bubble watchlist.”",
        "pubDate": "2025-10-23T10:30:00Z",
        "displayTime": "2025-10-23T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/933dc375e0ae0970794836b3bbdc7944",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "A view from inside a Tesla car looks out onto one of the company's dealerships, where flags with the Tesla logo hang.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3ZJzaMGXU13QEod70IffHg--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/933dc375e0ae0970794836b3bbdc7944.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_w7yraoD4b6J4d5zF1IuRA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/933dc375e0ae0970794836b3bbdc7944.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/technology/artificial-intelligence/tesla-kicks-off-mag-7-earnings-season/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/good-omen-bad-tesla-opens-103000911.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "GOOGL"
            },
            {
              "symbol": "AMZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T10:30:00+00:00",
    "headline": "Gold Rush Loses Momentum in Runup to Newmont Earnings",
    "summary": "Even with this week’s tumble, bullion investors can take gold comfort in knowing the noble metal is headed for its best year since 1979.",
    "url": "https://www.thedailyupside.com/finance/markets/golds-second-downward-day-tees-up-newmont-earnings/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "64081b5a-bbfd-3c59-9704-261fe027d7d5",
      "content": {
        "id": "64081b5a-bbfd-3c59-9704-261fe027d7d5",
        "contentType": "STORY",
        "title": "Gold Rush Loses Momentum in Runup to Newmont Earnings",
        "description": "",
        "summary": "Even with this week’s tumble, bullion investors can take gold comfort in knowing the noble metal is headed for its best year since 1979.",
        "pubDate": "2025-10-23T10:30:00Z",
        "displayTime": "2025-10-23T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/ad2c8e2ffc713ab609f36d681ed13143",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "A series of stacked gold bars are shown up close.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oPjvgHc4Pp32w2LUsgFCaw--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/ad2c8e2ffc713ab609f36d681ed13143.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N45e7tWIRLgFJnVD1pbQKA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/ad2c8e2ffc713ab609f36d681ed13143.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/finance/markets/golds-second-downward-day-tees-up-newmont-earnings/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gold-rush-loses-momentum-runup-103000042.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GC=F"
            },
            {
              "symbol": "NEM"
            },
            {
              "symbol": "DX-Y.NYB"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T04:03:00+00:00",
    "headline": "Eli Lilly (LLY): 3 Reasons We Love This Stock",
    "summary": "Since April 2025, Eli Lilly has been in a holding pattern, posting a small loss of 2.2% while floating around $811. The stock also fell short of the S&P 500’s 24.7% gain during that period.",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-3-reasons-040300334.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "23b895d1-9b76-3d5a-a565-ee0b0e68ce70",
      "content": {
        "id": "23b895d1-9b76-3d5a-a565-ee0b0e68ce70",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY): 3 Reasons We Love This Stock",
        "description": "",
        "summary": "Since April 2025, Eli Lilly has been in a holding pattern, posting a small loss of 2.2% while floating around $811. The stock also fell short of the S&P 500’s 24.7% gain during that period.",
        "pubDate": "2025-10-23T04:03:00Z",
        "displayTime": "2025-10-23T04:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "LLY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y7jUkGcVljBpqcrgSnimZQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fw6rZdJZ6CRFkLxhDmPhew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/2d0b545c448821f8d1ada0dbe955b186.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-3-reasons-040300334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-3-reasons-040300334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T02:35:27+00:00",
    "headline": "Why is Eli Lilly and Company (LLY) One of the Best Long Term Low Volatility Stocks to Buy Right Now?",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P. Morgan analyst Chris Schott maintained a bullish stance on Eli Lilly and Company (NYSE:LLY), keeping his Buy rating. The same day, Eli Lilly and Company (NYSE:LLY) announced results from the primary overall […]",
    "url": "https://finance.yahoo.com/news/why-eli-lilly-company-lly-023527546.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "23551a6e-e868-3c4e-ab4e-548fb57ebcdf",
      "content": {
        "id": "23551a6e-e868-3c4e-ab4e-548fb57ebcdf",
        "contentType": "STORY",
        "title": "Why is Eli Lilly and Company (LLY) One of the Best Long Term Low Volatility Stocks to Buy Right Now?",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P. Morgan analyst Chris Schott maintained a bullish stance on Eli Lilly and Company (NYSE:LLY), keeping his Buy rating. The same day, Eli Lilly and Company (NYSE:LLY) announced results from the primary overall […]",
        "pubDate": "2025-10-23T02:35:27Z",
        "displayTime": "2025-10-23T02:35:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Erste Group Upgrades Eli Lilly (LLY) to Buy Following Strong First-Half Results",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-company-lly-023527546.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-company-lly-023527546.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-23T02:09:54+00:00",
    "headline": "Sizing Up Eli Lilly After Obesity and Alzheimer’s Advances and a 7% Price Jump",
    "summary": "Thinking about what to do with Eli Lilly shares? You’re certainly not alone. The stock has been climbing the leaderboard for years, with a staggering 554.4% return over five years and 132.8% gains for anyone holding on since mid-2021. But if you’ve checked your portfolio lately, you might have noticed a few unexpected moves. Over the last month, Lilly edged up 7.6%, even in the face of a minor 1.7% slip for the week. For the year, it’s showing a modest 4.4% climb, but that’s coming off last...",
    "url": "https://finance.yahoo.com/news/sizing-eli-lilly-obesity-alzheimer-020954913.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ea3081b3-8e45-38e0-b0a2-e876218d28f5",
      "content": {
        "id": "ea3081b3-8e45-38e0-b0a2-e876218d28f5",
        "contentType": "STORY",
        "title": "Sizing Up Eli Lilly After Obesity and Alzheimer’s Advances and a 7% Price Jump",
        "description": "",
        "summary": "Thinking about what to do with Eli Lilly shares? You’re certainly not alone. The stock has been climbing the leaderboard for years, with a staggering 554.4% return over five years and 132.8% gains for anyone holding on since mid-2021. But if you’ve checked your portfolio lately, you might have noticed a few unexpected moves. Over the last month, Lilly edged up 7.6%, even in the face of a minor 1.7% slip for the week. For the year, it’s showing a modest 4.4% climb, but that’s coming off last...",
        "pubDate": "2025-10-23T02:09:54Z",
        "displayTime": "2025-10-23T02:09:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sizing-eli-lilly-obesity-alzheimer-020954913.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sizing-eli-lilly-obesity-alzheimer-020954913.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]